Jun 21, 2018
CytoDyn’s injectable PRO 140 is proving to be an effective treatment for multidrug-resistant HIV, Healio reports.
Presenting their findings at the ASM Microbe conference in Atlanta, researchers conducted a study of the investigational humanized monoclonal antibody PRO 140 among 50 people who had HIV that was resistant to at least two antiretroviral (ARV) drug classes. All the participants were infected with HIV that is CCR5-tropic, meaning the virus attaches to the CCR5 coreceptor on the surface of CD4 cells (as opposed to the CXCR4 coreceptor). PRO 140 works by blocking HIV from binding to the CCR5 coreceptor.
